Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction (original) (raw)
Editorial commentary: fifteen years of protection by meningococcal C conjugate vaccines: lessons from disease surveillance
Jenny Maclennan
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014
View PDFchevron_right
Prevalence of Serum Bactericidal Antibody to Serogroup C Neisseria meningitidis in England a Decade after Vaccine Introduction
Mary Ramsay
Clinical and Vaccine Immunology, 2012
View PDFchevron_right
Evidence for Rise in Meningococcal Serogroup C Bactericidal Antibody Titers in the Absence of Booster Vaccination in Previously Vaccinated Children
Mohamed Tashani
The Pediatric infectious disease journal, 2017
View PDFchevron_right
Safety and Immunogenicity of Coadministering a Combined Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine with 7-Valent Pneumococcal Conjugate Vaccine and Measles, Mumps, and Rubella Vaccine at 12 Months of Age
H. Findlow
Clinical and Vaccine Immunology, 2011
View PDFchevron_right
A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants
Mike English
Vaccine, 2000
View PDFchevron_right
Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England
Mary Ramsay
New England Journal of Medicine, 2020
View PDFchevron_right
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
Daniela Toneatto
Lancet, 2013
View PDFchevron_right
Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom
Michael Hudson
2009
View PDFchevron_right
Evaluation of the Impact of Meningococcal Serogroup A Conjugate Vaccine Introduction on Second-Year-of-Life Vaccination Coverage in Burkina Faso
Imran Mirza
The Journal of Infectious Diseases, 2019
View PDFchevron_right
Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: Interim analysis
Otto Vanderkooi
Vaccine, 2012
View PDFchevron_right
Effectiveness of Serogroup C Meningococcal Polysaccharide Vaccine: Results from a Case‐Control Study in Quebec
Genevieve Deceuninck
Clinical Infectious Diseases, 2005
View PDFchevron_right
Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity
S. Tiendrebeogo
Clinical Infectious Diseases, 2013
View PDFchevron_right
Maintenance of Immune Response throughout Childhood following Serogroup C Meningococcal Conjugate Vaccination in Early Childhood
H. Findlow
Clinical and Vaccine Immunology, 2011
View PDFchevron_right
Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
Ana Belen Ibarz Pavon
The Journal of …, 2008
View PDFchevron_right
Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial
Simon Montalto
BMJ (Clinical research ed.), 2015
View PDFchevron_right
Impact of the introduction of pneumococcal conjugate vaccine on immunization coverage among infants
Henry Badji
2005
View PDFchevron_right
Economics of an Adolescent Meningococcal Conjugate Vaccination Catch-up Campaign in the United States
Colin Shepard
Clinical Infectious Diseases, 2008
View PDFchevron_right
Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age
Stephen Lockhart
Vaccine, 2001
View PDFchevron_right
Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs
Martin Maiden
Expert Review of Vaccines, 2009
View PDFchevron_right
Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial
Arnold Willemsen
Vaccine, 2018
View PDFchevron_right
Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial
Marco Calabresi
Vaccine, 2017
View PDFchevron_right
Safety of a new conjugate meningococcal C vaccine in infants
Lisa Danzig
Archives of Disease in Childhood, 2001
View PDFchevron_right
Vaccination against meningococcus C. vaccinal coverage in the French target population
Helene Lepetit
Médecine et Maladies Infectieuses, 2013
View PDFchevron_right
A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)
Roman Prymula
Human Vaccines & Immunotherapeutics, 2014
View PDFchevron_right
The Impact of Routine Immunization Using Meningococcal C Conjugate Vaccine on Invasive Meningococcal Disease in British Columbia
David Patrick
Canadian Journal of Public Health, 2008
View PDFchevron_right
Effectiveness of Serogroup C Meningococcal Conjugate Vaccine
Genevieve Deceuninck
The Pediatric Infectious Disease Journal, 2011
View PDFchevron_right
Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age
Alejandra Valencia
Vaccine, 2010
View PDFchevron_right
A Randomized, Multicenter, Open-Label Clinical Trial to Assess the Immunogenicity of a Meningococcal C Vaccine Booster Dose Administered to Children Aged 14 to 18 Months
Javier Díez-Domingo
Pediatric Infectious Disease Journal, 2010
View PDFchevron_right
Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT)
Veronique Bianco
International Journal of Infectious Diseases, 2013
View PDFchevron_right
Safety and Immunogenicity of Two Doses of Quadrivalent Meningococcal Conjugate Vaccine or One Dose of Meningococcal Group C Conjugate Vaccine, both Administered Concomitantly with Routine Immunization to 12- to 18-Month-Old Children
Himanshu Dubey
Canadian Journal of Infectious Diseases and Medical Microbiology, 2014
View PDFchevron_right
Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary‐School Children in 1999–2000 and Response to a Booster: A Phase 4 Clinical Trial
Elizabeth Kibwana
Clinical Infectious Diseases, 2010
View PDFchevron_right
‘On the spot’vaccination: Does it work?
Garth Alperstein
Journal of Paediatrics and Child Health, 1996
View PDFchevron_right